来源： 类型：
BEIJING, Dec. 30 (Xinhua) -- A Chinese inactivated vaccine shows 79.34percent efficacy against COVID-19, according to the interim results of thephase-3 clinical trials unveiled by its developer Wednesday.
The inactivated vaccine is developed by the Beijing Biological ProductsInstitute Co., Ltd. under the China National Biotec Group (CNBG), which is affiliatedto Sinopharm. After a two-dose inoculation procedure, the vaccine receivers allproduced high titers of antibodies, and the seroconversion rate of neutralizingantibodies reached 99.52 percent. The results meet the requirements of technical standards of the WorldHealth Organization and the standards stipulated by China's National MedicalProducts Administration (NMPA).
The company has submitted an application to the NMPA for conditionedmarket approval.
